Pyxis Oncology Advances MICVO Toward Phase 3 in HNSCC
BOSTON — September 9, 2026 Pyxis Oncology, Inc. announced positive updated data from its ongoing Phase 1 monotherapy study...
Immuno-Oncology
Advertisement
Context Therapeutics Doses First Patient in CT-202 Phase 1
PHILADELPHIA — September 9, 2026 Context Therapeutics Inc. announced that the first patient has been dosed in the Phase...
Inhibrx to Present INBRX-106 Phase 2 HNSCC Results
San Diego, California, USA, September 4, 2026 Inhibrx Biosciences, Inc. has announced plans to host a live webcast presentation...
Heartvue.ai and Innolitics Gain FDA Clearance for Cardiac MRI AI
Brentwood, Tennessee & Austin, Texas, USA, September 3, 2026 Heartvue.ai and Innolitics have announced that the U.S. Food and...
Akeso Reports Ivonescimab OS Benefit in HARMONi-2
Hong Kong, September 3, 2026 Akeso, Inc. has announced that a prespecified interim analysis of overall survival (OS) in...
Advertisements
HUTCHMED and GSK Partner on KRAS-EGFR Cancer Therapy
Hong Kong, Shanghai & Florham Park, New Jersey, USA, September 3, 2026 HUTCHMED (China) Limited and GSK have entered...
Agenus Reports Durable BOT+BAL Activity in MSS Colorectal Cancer
Lexington, Mass. – August 28, 2026 Agenus Inc. announced the publication of mature Phase 1b results evaluating botensilimab (BOT)...
Akeso Reports 2026 Growth, Advances Global Drug Pipeline
HONG KONG, Aug 27, 2026 Akeso, Inc. announced its 2026 interim results, reporting record commercial drug sales while advancing...
Daiichi Sankyo Begins Phase 1 Trial of CD25 ADC DS1025
Tokyo, Japan – August 27, 2026 Daiichi Sankyo has entered a new phase of oncology development with the first...
HCW Biologics Advances TGF-β/IL-15 Cancer Immunotherapy
Miramar, Fla. – August 25, 2026 HCW Biologics announced new findings supporting its TGF-β trap and IL-15 fusion moiety...
Advertisement
